This Phase II, parallel-group, masked, randomized clinical trial aims to evaluate whether a DHA/ARA-enriched, fortified human milk diet administered during the first 14 days of life reduces respiratory morbidity and improves lung function in extremely preterm (EPT) infants (born at ≤28 weeks gestation).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Severity of respiratory morbidity
Timeframe: 0 - 120 days
Non-invasive impulse oscillometry measurements of pulmonary mechanics
Timeframe: 40 - 120 days